CLINICAL TRIALS PROFILE FOR LORATADINE

505(b)(2) Clinical Trials for LORATADINE

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
OTC	NCT01469234 ↗	A Study of Onset of Action of Loratadine and Fexofenadine in Participants With Seasonal Allergic Rhinitis (P08712)	Completed	Bayer	Phase 4	2011-10-01	The purpose of this study is to determine the onset of action of two commercially available over-the-counter antihistamines (Loratadine and Fexofenadine) in a model of seasonal allergic rhinitis (SAR). Participants undergo sensitization exposures to Mountain Cedar (juniperus ashei) pollen in a Biogenics Research Chamber; those who demonstrate an adequate allergic response determined by the Major Symptom Complex (MSC) score will then receive drug.

All Clinical Trials for LORATADINE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00319995 ↗	Effects of Loratadine/Montelukast vs Pseudoephedrine and Placebo in Patients With Seasonal Allergic Rhinitis (Study P04095) (COMPLETED)	Completed	Merck Sharp & Dohme Corp.	Phase 3	2006-03-01	This is a Phase 3, randomized, parallel-group, multicenter, double-dummy, double-blind study with a screening period. Subjects will receive one of the following three treatment groups for 15 days: loratadine 10 mg/montelukast 10 mg combination, pseudoephedrine 240 mg, or placebo. The primary objective of this study is to assess the efficacy of the combination of loratadine/montelukast, a once-daily tablet containing 10 mg loratadine and 10 mg montelukast, compared with placebo in subjects with seasonal allergic rhinitis (SAR) in relieving the symptom of nasal congestion. The safety profile of combined loratadine/montelukast relative to placebo and pseudoephedrine will also be evaluated.
NCT00423995 ↗	Effect of Loratadine/Montelukast Combination on Congestion in SAR Patients Exposed to Pollen in an EEU (Study P04822)	Completed	Merck Sharp & Dohme Corp.	Phase 3	2006-11-01	This is study of LMC, phenylephrine, and placebo in subjects with SAR. There are three visits: At Visit 1, subjects will be evaluated for participation and, if they qualify, will attend Visit 2 for priming. At Visit 2, ragweed pollen will be fed continuously and dispensed into the environmental exposure unit to induce an allergic reaction. Pollen counts will be monitored and recorded. During the priming visit(s), subjects will be evaluated to determine if they qualify. If qualified, they will return for Visit 3, where ragweed pollen will be fed continuously and dispensed into the environmental exposure unit to induce an allergic reaction. Pollen counts will be monitored and recorded as in the Priming Session. Subjects will complete symptom evaluations and if qualified, they will receive study medication and remain in the environmental exposure unit where symptoms will be evaluated for 8 hours after dosing. PNIF will be evaluated only during the treatment session. Four nasal symptoms (rhinorrhea, nasal congestion, sneezing, and nasal itching) and three non-nasal symptoms (itching/burning eyes, tearing/watery eyes, and itching of ears/palate) will be evaluated. Adverse events will be collected throughout the study to assess safety and tolerability, and vital signs will be collected at Visit 1 and at the end of Visit 3.
NCT00481676 ↗	Efficacy and Safety of Omalizumab in Adults (18-70 Years) With Moderate to Severe Chronic Urticaria	Completed	Novartis	Phase 2	2007-05-01	This study evaluated the safety and efficacy of omalizumab in adult patients with moderate to severe chronic urticaria who exhibit IgE against thyroperoxidase.
NCT00524836 ↗	Efficacy and Safety of Levocetirizine Versus Loratadine for the Treatment of Perennial Allergic Rhinitis	Completed	UCB Pharma	Phase 3	2003-09-01	Efficacy and Safety of Levocetirizine Versus Loratadine for the Treatment of Perennial Allergic Rhinitis.
NCT00525278 ↗	To Evaluate the Efficacy and Safety of Levocetirizine Versus Loratadine for Treatment of Seasonal Allergic Rhinitis	Completed	UCB Pharma	Phase 3	2003-08-01	To Evaluate the Efficacy and Safety of Levocetirizine Versus Loratadine for Treatment of Seasonal Allergic Rhinitis
NCT00525382 ↗	Study to Compare the Efficacy and Safety Between Levocetirizine and Loratadine for Chronic Idiopathic Urticaria	Completed	UCB Pharma	Phase 3	2003-08-01	Study to Compare the Efficacy and Safety Between Levocetirizine and Loratadine for Chronic Idiopathic Urticaria.

Clinical Trial Conditions for LORATADINE

Condition Name

Condition Name for LORATADINE
Intervention	Trials
Seasonal Allergic Rhinitis	9
Healthy	6
Allergic Rhinitis	5
Rhinitis	5

Condition MeSH

Condition MeSH for LORATADINE
Intervention	Trials
Rhinitis, Allergic	28
Rhinitis	28
Rhinitis, Allergic, Seasonal	17
Rhinitis, Allergic, Perennial	7

Clinical Trial Locations for LORATADINE

Trials by Country

Trials by Country for LORATADINE
Location	Trials
United States	84
China	18
Canada	8
Spain	3
Germany	3

Trials by US State

Trials by US State for LORATADINE
Location	Trials
New York	5
New Jersey	5
Michigan	4
Maryland	4
Georgia	4

Clinical Trial Progress for LORATADINE

Clinical Trial Phase

Clinical Trial Phase for LORATADINE
Clinical Trial Phase	Trials
PHASE4	1
PHASE3	1
PHASE2	2

Clinical Trial Status

Clinical Trial Status for LORATADINE
Clinical Trial Phase	Trials
Completed	52
RECRUITING	4
Not yet recruiting	4

Clinical Trial Sponsors for LORATADINE

Sponsor Name

Sponsor Name for LORATADINE
Sponsor	Trials
Merck Sharp & Dohme Corp.	14
Bayer	7
Ranbaxy Laboratories Limited	4

Sponsor Type

Sponsor Type for LORATADINE
Sponsor	Trials
Industry	49
Other	35
NIH	4

LORATADINE Market Analysis and Financial Projection

Last updated: April 24, 2026

Loratadine: Clinical Trial Update, Market Analysis, and Projection

What is loratadine’s current clinical-trial profile?

Loratadine is an established, off-patent second-generation antihistamine marketed globally for allergic rhinitis and chronic idiopathic urticaria. The clinical-trial “update” in 2026 is dominated by confirmatory pharmacology, bioequivalence (BE) and formulation work, rather than new, mechanism-expanding phase programs.

Trial activity pattern (what remains active in the pipeline):

• Bioequivalence and formulation studies across tablets, orally disintegrating tablets (ODTs), syrups, and generic versions
• Population and tolerability studies that support labeling, pediatric dosing, and excipient changes
• Post-marketing comparative effectiveness trials in allergic rhinitis and urticaria settings (often pragmatic, country-specific)

What does this mean for R&D commitments?

• The R&D center of gravity is shifted to product lifecycle management: reformulation, BE, manufacturing changes, and line extensions that can be executed without displacing existing therapeutic standards.
• No credible signal of a late-stage “new loratadine” development path that would materially change efficacy or differentiated competitive positioning is visible from the public clinical-trial record for this molecule.

Key regulatory anchor (dose and indication basis):

• Standard adult and pediatric dosing is embedded in established labeling and does not typically drive new registrational phase trials. Loratadine’s ongoing clinical footprint is therefore mostly compliance-driven (BE and safety/tolerability).

Market-ready interpretation:

• For investors and R&D planners, loratadine’s clinical-trial cycle is now mostly generic ecosystem execution rather than innovative pipeline creation.

---

How large is the loratadine market today, and what segments matter?

Loratadine competes in a crowded, mature antihistamine market alongside cetirizine, levocetirizine, fexofenadine, and desloratadine. Its commercial strength comes from:

• Broad prescriber and consumer familiarity
• Strong generics penetration
• Utility in both prescription and OTC channels in many regions

Segmentation that drives sales:

1. Allergic rhinitis: perennial and seasonal use dominates volume
2. Chronic idiopathic urticaria: sustained use supports repeat demand
3. Product form: tablets and syrups capture different patient populations; ODTs tend to trade at modestly higher price points in markets where they are established

Competitive set (practical substitute map):

• Cetirizine / levocetirizine: often the closest “switch” products in pharmacy decision-making
• Fexofenadine: competes on “non-sedating” positioning
• Desloratadine: overlaps for allergy/urticaria symptom control
• Other OTC antihistamines: vary by country and formulation availability

Commercial implication:

• Loratadine’s market share tends to track pricing and channel execution more than clinical differentiation.

---

What is the economics of loratadine pricing and generic competition?

Loratadine’s economics are shaped by the generic model:

• Low unit value relative to differentiated therapeutics
• High margin variability by region due to tendering, reimbursement, and pharmacy pricing controls
• Erosion risk is perpetual because BE-approved generics can enter and compress prices unless brands maintain distribution advantage

What typically preserves revenue in mature antihistamines:

• Tight supply-chain reliability and predictable manufacturing costs
• Strong OTC retail footprint
• Pediatric and syrup formats that match local guideline preference
• Formulation differentiation that is sufficient to support shelf pricing, even without new efficacy claims

---

What are the market drivers behind projected demand growth?

Demand growth for loratadine is structurally supported by:

• Persistent prevalence of allergic rhinitis
• Ongoing consumer and household purchasing of OTC antihistamines
• Continuing need for chronic symptom management in urticaria cohorts

Offsetting headwinds:

• Substitution into competing antihistamines with favorable “sedation” perceptions and brand equity
• Continued generic price pressure
• Regulatory and reimbursement changes that shift coverage toward alternative agents

---

What is the projection for loratadine over the next 5 years?

Because loratadine is mature and heavily genericized, the most defensible projection framework is:

• Volume: modest growth tied to population and allergic disease burden
• Value: flat to low-growth due to price compression, with localized bumps from mix (ODT/syrup) and channel dynamics

Practical projection statement (business use):

• Expect steady-to-modest volume growth and gradual value erosion unless a producer achieves mix gains (higher-margin formats), cost leadership, or channel consolidation.

Why not a high-variance upside?

• Loratadine has no obvious late-stage “step-change” clinical development that would re-rate competitive positioning.
• Market behavior in mature antihistamines is dominated by pricing and distribution rather than evidence of superior outcomes.

---

Where does loratadine fit in current competitive strategy?

Loratadine remains a workhorse antihistamine for:

• Cost-sensitive healthcare systems
• Mass-market OTC distribution
• Multi-form pediatric strategies (syrup) and adherence-focused forms (ODT where supported)

Strategy choices that matter commercially:

• Manufacturing cost leadership (scale and yield)
• Portfolio defense through line extensions (e.g., ODT, flavor/formulation) that do not require new clinical proof beyond BE
• Channel depth in pharmacy chains and tender ecosystems
• Localized labeling optimization where regulatory approvals permit

---

Key Takeaways

• Loratadine’s clinical activity is dominated by bioequivalence, formulation, and compliance studies, consistent with an off-patent, mature antihistamine profile.
• Market performance is driven by pricing, OTC/channel execution, and product mix, not new clinical differentiation.
• Projections for the next 5 years are best framed as modest volume growth with value pressure, unless a producer sustains cost leadership or mix gains.

---

FAQs

1. Is loratadine still undergoing clinical trials in 2026?
   Yes, activity persists primarily through bioequivalence and formulation-related studies rather than novel late-stage clinical development.

2. What indications drive loratadine sales?
   Allergic rhinitis and chronic idiopathic urticaria.

3. How does loratadine compete against cetirizine and fexofenadine?
   Competition is largely channel and pricing driven, with substitution occurring based on perceived sedation profile and brand or pharmacy preference.

4. What product forms matter most commercially?
   Tablets and syrups dominate; orally disintegrating formats can improve mix and reduce adherence friction where they have market pull.

5. What is the highest-risk factor for revenue in loratadine?
   Ongoing generic entry and persistent price compression in mature antihistamine markets.

---

References

[1] U.S. Food and Drug Administration. “Drug Trials Snapshots: Loratadine.” FDA. https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots
[2] DailyMed. “Claritin (Loratadine) Drug Label.” U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/
[3] World Health Organization. “Allergic rhinitis” and related guidance resources (general condition background). WHO. https://www.who.int/